Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panitumumab - Amgen

Drug Profile

Panitumumab - Amgen

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; Clone-E7.6.3; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 28 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Grupo Espanol Multidisciplinario del Cancer Digestivo; Netherlands Cancer Institute; Novartis; Takeda; University of Texas M. D. Anderson Cancer Center; Wissenschaftlicher Service Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Anal cancer; Bladder cancer; Breast cancer; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for phase-I development in Bladder-cancer(Second-line therapy or greater) in Netherlands (IV, Infusion)
  • 12 Oct 2018 Amgen completes a phase I trial in Bladder cancer (Second-line therapy or greater) in Netherlands (IV) (NTR3157)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top